Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer

Lung Cancer

Volumn 53, Issue 1, 2006, Pages 97-101

  Jones, J Mark ^a   McGonigle, Niall C ^a   McAnespie, Martin ^a   Cran, Gordon W ^b   Graham, Alastair N ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

C reactive protein; Fibrinogen; Inflammatory mediators; Molecular biology; Non small cell lung cancer

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURGICAL TECHNIQUE; THORACOTOMY; TUMOR VOLUME;

ADENOCARCINOMA; AGED; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FIBRINOGEN; HUMANS; LUNG NEOPLASMS; MALE; PREOPERATIVE CARE; PROGNOSIS;

EID: 33744830039     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.03.012     Document Type: Article

References (29)

1. Tanoue L.T., and Matthay R.A. Lung cancer: epidemiology and carcinogenesis. In: Shields T.W., LoCicero J., and Ponn R.B. (Eds). General thoracic surgery. 5th ed. (2000), Lippincott, Williams and Wilkins, Phildelphia 1215-1228
2. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris. Paris: J-B Balliere et Fils; 1865. p. 654-712.
3. Wojtukiewicz M.Z., Zacharski L.R., Moritz T.E., Hur K., Edwards R.L., and Rickles F.R. Prognostic significance of blood coagulation tests in carcinoma of the lung and colon. Blood Coagul Fibrinolysis 3 (1992) 429-437
4. Seitz R., Rappe N., Kraus M., Immel A., Wolf M., Maasberg M., et al. Activation of coagulation and fibrinolysis in patients with lung cancer: relation to tumour stage and prognosis. Blood Coagul Fibrinolysis 4 (1993) 249-254
5. Buccheri G., Ferrigno D., Ginardi C., and Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 33 (1997) 50-55
6. Ferrigno D., Buccheri G., and Ricca I. Prognostic significance of blood coagulation tests in lung cancer. Eur Respir J 17 (2001) 667-673
7. Pavey S.J., Hawson G.A.T., and Marsh N.A. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinloysis 12 (2001) 51-58
8. McMillan D.C., Canna K., and McArdle C.S. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg 90 (2003) 215-219
9. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
10. Glazer H.S., Duncan-Meyer J., Aronberg D.J., Moran J.F., Levitt R.G., and Sagel S.S. Pleural and chest wall invasion in bronchogenic carcinoma: CT evaluation. Radiology 157 (1985) 191-194
11. Glazer H.S., Kaiser L.R., Anderson D.J., Molina P.L., Emami B., Roper C.L., et al. Indeterminate mediastinal invasion in bronchogenic carcinoma: CT evaluation. Radiology 173 (1989) 37-42
12. Fernando H.C., and Goldstraw P. The accuracy of clinical evaluative intrathoracic staging in lung cancer as assessed by postsurgical pathologic staging. Cancer 65 (1990) 2503-2506
13. Webb W.R., Gatsonis C., Zerhouni E.A., Heelan R.T., Glazer G.M., Francis I.R., et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 178 (1991) 705-713
14. Gonzalez-Stawinski G.V., Lemaire A., Merchant F., O'Halloran E., Coleman R.E., Harpole D.H., et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1900-1905
15. Reed C.E., Harpole D.H., Posther K.E., Woolson S.L., Downey R.J., Meyers B.F., et al. American College of Surgeons Oncology Group Z0050 trial. Results of the American College of Surgeons Oncology group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126 (2003) 1943-1951
16. Kelly R.F., Tran T., Holmstrom A., Murar J., and Segurola Jr. R.J. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-d-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 125 (2004) 1413-1423
17. Ploeg A.J., Kappetein A.P., van Tongeren R.B., Pahlplatz P.V., Kastelein G.W., and Breslau P.J. Factors associated with perioperative complications and long term results after pulmonary resection for primary carcinoma of the lung. Eur J Cardiothorac Surg 23 (2003) 26-29
18. Glazer G.M., Gross B.H., Quint L.E., Francis I.R., Bookstein F.L., and Orringer M.B. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. Am J Roentgenol 144 (1985) 261-265
19. Lau C.L., Harpole D.H., and Patz E. Staging techniques for lung cancer. Chest Surg Clin N Am 10 (2000) 781-801
20. Graham A.N., Chan K.J., Pastorino U., and Goldstraw P. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 117 (1999) 246-251
21. Palumbo J.S., Kombrinck K.W., Drew A.F., Grimes T.S., Kiser J.H., Degen J.L., et al. Fibrinogen is an important determinant of the metastatic potential of circulation tumour cells. Blood 96 (2000) 3302-3309
22. Simpson-Haidaris P.J., and Rybarczyk B. Tumours and fibrinogen: the role of fibrinogen as an extracellular matrix protein. Ann NY Acad Sci 936 (2001) 406-425
23. Dvorak H.F. Tumours: wounds that do not heal. Similarities between tumour stroma generation and wound healing. N Engl J Med 315 (1986) 1650-1659
24. Biggerstaff J.P., Seth N.B., Meyer T.V., Amirkhosravi A., and Francis J.L. Fibrin monomer increases platelet adherence to tumor cells in a flowing system: a possible role in metastasis?. Thromb Res 92 (1998) S53-S58
25. Biggerstaff J.P., Seth N.B., Amirkhosravi A., Amaya M., Fogarty S., Meyer T.V., et al. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 17 (1999) 723-730
26. Palumbo J.S., Potter J.M., Kaplan L.S., Talmage K., Jackson D.G., and Degen J.L. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62 (2002) 6966-6972
27. Kalweit G.A., Feindt P., Micek M., Gams E., and Hellstern P. Markers of activated hemostasis and fibrinlysis in patients with pulmonary malignancies: comparison of plasma levels in central venous and pulmonary venous blood. Thromb Res 97 (2000) 105-111
28. Fearon K.C., Barber M.D., Falconer J.S., McMillan D.C., Ross J.A., and Preston T. Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. World J Surg 23 (1999) 584-588
29. Dirix L.Y., Salgado R., Weytjens R., Colpaert C., Benoy I., Huget P., et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 86 (2002) 389-395